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Taxane-containing chemotherapy in the treatment of
early breast cancer patients
M. Clavarezza1, L. Del Mastro1 & M. Venturini2,3*
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In primary breast cancer, taxane-based compared with anthracycline-based adjuvant chemotherapy
significantly reduces the relative risk of recurrence (ranging from 17% to 36%) and sometimes improves overall
survival. Different dosages and schedules of anthracyclines and taxanes have been tested. Randomized studies
comparing sequential versus concurrent administrations are in progress and no data about efficacy are
available. However, based on a single randomized trial and on indirect comparisons, safety and tolerability seem
to be better with sequential schema. A formal comparison between weekly and every 3 weeks administration of
taxanes reported no substantial difference in terms of efficacy. However, taking into account a subgroup
analysis of this study, and results coming from metastatic disease, the best way to give taxanes seems to be
either weekly paclitaxel or docetaxel every 3 weeks. In the majority of the study, taxane efficacy seems to be
independent of hormonal receptor status, i.e. active in both hormonal receptor positive and negative disease. In
conclusion, taxane-based adjuvant chemotherapy is a standard option for most early breast cancer patients
with node-positive disease. No sufficient and dedicated data are available in node-negative disease.
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sequential or concomitant schedule:
which is better?
Six randomized phase III trials (CALGB 9344 [1], NSABP B-28
[2], PACS 01 [3], GEICAM 9906 [4] and MDACC 94–002 [5])
(Table 1) evaluated the efficacy of taxanes given sequentially to
anthracyclines compared with anthracyclines-based regimens as
adjuvant chemotherapy for operable breast cancer. A total of
nearly 10 000 node-positive patients entered these studies.
CALGB 9344 and NSABP B-28 used, as the control arm, four
cycles of standard doxorubicin–cyclophosphamide (AC), while
PACS 01, GEICAM 9906 and MDACC 94–002 had a more
adequate control arm (i.e. FE100C ·6, FE90C ·6, FA50C ·8,
respectively). All these trials, with the exclusion of MDACC
94–002, demonstrated a statistically significant improvement in
disease free-survival (DFS) in favor of taxanes-containing
chemotherapy with a relative reduction of relapse ranging from
17% to 36% and with an absolute benefit of 4%–6%. Moreover,
two studies (CALGB 9344 and PACS 01) also demonstrated
a statistically significant benefit on overall survival with
a relative reduction of risk of death of 18% (HR = 0.82, CI
95% 0.71–0.95; P = 0.0064; CALGB) and of 23% (HR = 0.77, CI
95% 0.59–1.00; P = 0.017; PACS 01), respectively. Grade 3–4
toxicity analysis of sequential schedules is shown in Table 2.
Absolute increase (+) or decrease () in toxicity due to taxanes
compared with control arms are reported. Sequential docetaxel
is associated with more febrile neutropenia, edema and nail
disorders, while sequential paclitaxel is associated with more
neuropathy and arthralgia/myalgia.
Four randomized trials (BCIRG 001 [6], E2197 [7], RAPP 01
[8] and ECTO [9]) (Table 1) evaluated the efficacy of taxanes-
based chemotherapy given concurrently with anthracyclines
compared with anthracyclines-based chemotherapy. More than
5000 patients were enrolled. BCIRG 001 tested a triplet
combination containing anthracyclines and taxanes given
concurrently (TAC: docetaxel 75 mg/m2, doxorubicin
50 mg/m2, cyclophosphamide 500 mg/m2) compared with
FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2,
cyclophosphamide 500 mg/m2) and demonstrated a statistically
significant improvement both in DFS (HR = 0.72, CI 95%
0.59–0.88; P = 0.001) and overall survival (OS) (HR = 0.70,
CI 95% 0.53–0.91; P = 0.008), with an absolute benefit of 7%
and 6%, respectively. E2197 [7] compared AT (docetaxel)
versus standard AC. No differences in both DFS (HR = 1.03,
CI 95% 0.86–1.25; P = 0.70) and OS (HR = 1.09, CI 95%
0.85–1.40; P = 0.49) were observed. ECTO [9] was designed
to study the addition of paclitaxel concurrently with
anthracyclines (followed by cyclophosphamide, methotrexate
and fluorouracil; CMF). At 31 months follow-up, a benefit
in freedom from progression was observed in the paclitaxel
arm (HR = 0.65, CI 95% 0.47–0.90; P = 0.01). No efficacy
data are available for RAPP 01.
Table 3 shows grade 3–4 toxicity profile of concurrent
paclitaxel and concurrent docetaxel. Absolute increase (+) or
decrease () in toxicity due to taxanes compared with control
arms are shown. Chemotherapy with combined anthracyclines
and adequate doses of docetaxel (i.e. 75 mg/m2) requires
antibiotic prophylaxis and G-CSF support (13%–34% increase
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Table 1. Trials of adjuvant chemotherapy containing taxanes divided by sequential and concurrent schedules, by different taxanes schedules and by taxanes versus anthracyclines
Study Random FUa No. of
patients
Inclusion
criteria
Median
age
Premenopausal
(%) or <50
years (%)
N ‡4
(%)
HR–
(%)
HER2+
(%)
Disease-free
survival
Subgroup analysis
(benefit)
Overall survival
Sequential taxanes
CALGB 9344 [1] A (60/75/90) C 600 · 4 +/ 69 3121 Node+ NR 60% 54% 34% NR HR 0.83 HR only HR 0.82
P 175 · 4 P = 0.0023 P = 0.0064
NSABP B28 [2] AC (60/600) · 4 65 3060 Node+ NR 50% 30% 34% (ER) NR HR 0.83 HR+ only HR 0.93
AC (60/600) · 4 – P 225 · 4 P = 0.006 P = 0.46
PACS 01 [3] FEC (500/100/500) · 6 60 1999 Node+ 50 50% 38% 21% NR HR 0.83 Postmenopausal HR 0.77
FEC · 3 – D 100 · 3 P = 0.014 N 1–3 P = 0.017
GEICAM 9906 [4] FEC (600/90/600) · 6 47 1248 Node+ 50 55% 38% 20% 15% HR 0.64 Postmenopausal HR 0.74
FEC · 4 (600/90/600) –
wP100 · 8
P = 0.0009 N 1–3 P = 0.1375
HR + and HR–
HER2 + and HER2
MDACC 94–002 [5] FAC (500 d1-8/50/500) · 8 60 524 Stage NR 56% 34% 37% (ER) NR HR 0.70 Better benefit ER NR
P 250 · 4 – FAC · 4 I–IIIB P = 0.09
Concurrent taxanes
BCIRG 001 [6] DAC (75/50/500) · 6 55 1491 Node+ 49 56% 38% 24% 21% HR 0.72 N 1–3 HR 0.70
FAC (500/50/500) · 6 P = 0.0010 HR+ and HR- P = 0.0080
HER2 + and HER2
ECTO [9] A · 4 – CMF · 4 31 1355 T >2 cm NR 44% NA 31% NR HR 0.66 HR – for PST HR 0.71
AT · 4 – CMF · 4 P = 0.01 P = 0.71
AT · 4 – CMF · 4 (PST)
E2197 [7] AT (60/60) · 4 53 2952 N 1–3 51 NR NR 35% (ER) NR HR 1.03 Better benefit HR HR 1.09
AC (60/600) · 4 Node – and
T >1 cm
65% N- P = 0.70 ER+ PR- P = 0.49
RAPP 01 [8] AC (60/600) · 4 24 627 N 1–3 52 47% 0% 19% 11% NR NR NR
AT 60/75) · 4 N- High risk
Different taxane schedules
INT E1199 [14] AC (60/600) ·4,
followed by
46 4988 Node + Node-
and T ‡2 cm
51 46% 33% 27% 20% P versus D Better trend with NS (HR not
reported)
P 175 · 4 HR 0.985 Weekly Paclitaxel
wP 80 · 12 P = 0.83 3-weeks Docetaxel
D 100 · 4 q3w versus w
wD 35 · 12 HR 1.043
P = 0.54
AC-P versus AC (60/600) · 4 – P 175 · 4 36 1830 N+ 52 33% 27% 35% NR HR 0.74 NR HR 0.65
AP-wP [15] AP (50/200) · 4 – wP 80 · 12 N and T >2 cm
HR+
P = 0.050 P = 0.005
N and T >1 cm
HR
Taxanes versus anthracyclines
USOR [16] AC (60/600) · 4 60 1016 Stage I–III 52 NR 11% 28% NR HR 0.67 NR HR 0.76
DC (75/600) · 4 (Stage III: 7%) P = 0.015 P = 0.131
A, adriamicin; C, cyclophosphamide; P, paclitaxel; wP, weekly paclitaxel; F, fluorouracil; E, epirubicin; D, docetaxel; wD, weekly docetaxel; M, methotrexate; PST, primary systemic therapy.
aFU, median follow-up; NR, not reported; NA, not applicable; NS, not significant; N, number of positive nodes; HR, hormonal receptor negative; ER, estrogen receptor; PR, progesterone receptor; HR, hazard ratio;
q3w, schedules every 3 weeks; w, weekly schedules.
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in febrile neutropenia) and is also associated with more anemia,
stomatitis and nail disorders. Furthermore, RAPP 01 [8] trial
was prematurely closed because of higher risk of life-threatening
complications with doxorubicin–docetaxel regimen (AT)
compared to doxorubicin–cyclophosphamide (AC), in
particular febrile neutropenia (40.8% versus 7.1%, P <0.001),
with three deaths in the AT arm (doses: adriamicin 60 mg/m2,
docetaxel 75 mg/m2 every 3 weeks). Of note, antibiotic
prophylaxis was not given in this study. The addition of
paclitaxel, concomitantly with anthracyclines at full doses
(paclitaxel 200 mg/m2 concurrent with doxorubicin 60 mg/m2
every 3 weeks) significantly increased grade 2–3 neuropathy
(grade 2: 20.5% versus 5.0%; grade 3: 1.3% versus 0.2%) and
marginally increased febrile neutropenia.
Overall, no efficacy data exist on direct comparison between
sequential and concurrent schedules. Only one study, BCIRG
005 [10], compares TAC regimen with AC followed by docetaxel
and, actually, only data about toxicities are known: TAC is
associated with a statistically significant increased febrile
neutropenia (17.9% versus 8.5%).
All taxanes schedules improve disease free-survival but
taxanes administered sequentially to anthracyclines appear to be
less toxic and more manageable than concurrent
administration.
which taxane is better: paclitaxel or
docetaxel? Weekly or every 3 weeks?
In metastatic breast cancer, paclitaxel showed a different
activity if given with a 3-week or with a weekly schedule. CALGB
9840 [11] compared two different schedules of paclitaxel:
80 mg/m2 on days 1, 8, 15 every 28 days and 175 mg/m2 every
three weeks every 21 days. Results of this study demonstrated
a statistically higher activity of weekly schedule in terms of
response rate (40% versus 28%; HR = 1.61, P = 0.017) and time
to progression (9.0 months versus 5.0 months; HR = 1.45,
P = 0.0008). Overall survival was not significantly different
(24 months versus 16 months; HR = 1.19, P = 0.17). Another
study [12] was designed to evaluate activity and efficacy of
docetaxel given weekly or every 3 weeks (doses: 40 mg/m2
weekly consecutively for 6 weeks every 8 weeks compared to
100 mg/m2 every 3 weeks). Results showed no difference in
terms of activity (response rate: 34% versus 33%), time
progression (5.7 versus 5.3 months) and median overall survival
(29.1 versus 20.1 months). In the metastatic setting,
a randomized phase III trial also compared docetaxel and
paclitaxel [13]. Median overall survival (15.4 versus 12.7
months; HR = 1.41, P = 0.03), median time to progression
(5.7 versus 3.6 months; HR = 1.64, P < 0.001), were reported to
be better for the docetaxel arm.
Data in early breast cancer were recently presented at
S. Antonio Breast Cancer Symposium 2005. A factorial
randomized trial compared paclitaxel versus docetaxel and
weekly versus every 3 weeks schedule [14]. Overall, 4988
patients were analyzed. At a median follow-up of 46.5 months,
there were no differences in disease-free survival between
paclitaxel and docetaxel (HR = 0.985, CI 95% 0.84–1.15; P = 0.83)
and between every 3 weeks versus weekly schedule (HR = 1.043,
CI 95% 0.89–1.22; P = 0.54). An exploratory analysis showed
a trend for worse outcome with three weeks paclitaxel versus
weekly administration (HR = 1.20, CI 95% 0.99–1.46;
P = 0.06). Toxicity profile showed not great differences between
the two paclitaxel schedules: more neutropenia grade 3–4 was
associated with 3 weeks paclitaxel (4% versus 2%), while
neuropathy was typical with weekly paclitaxel (8% versus 4%).
Table 2. Grade 3–4 toxicities of sequential anthracyclines and taxanes
(docetaxel and paclitaxel) compared to non-taxanes regimes
Grade 3–4 toxicity Sequential docetaxel Sequential paclitaxel
FEC-D [3] AC-P [1, 2, 4]
Febrile neutropenia +4% +3%–7%
Infection +0% +1%
Nausea-Vomiting 9% 29% (also grade 2)
Stomatitis +2% 9% (also grade 2)
Nail disorders +9% NR
Edema +4% NR
Neurosensory–neuromotor +0% +3%–18%
Arthralgia/myalgia NR +2%–12%
Cardiac 1% 0.1%–0.4%
Toxic deaths +0% 0.2%
Table 3. Grade 3–4 toxicities of concurrent anthracyclines and taxanes
(docetaxel and paclitaxel) compared with non-taxanes regimens
Grade 3–4 toxicity Concurrent docetaxel Concurrent paclitaxel
DAC [6]; A60D60 [7];
A60D60 [8]
AP-CMF [9]
Febrile neutropenia +13%–34% +2%
Anemia requiring
transfusions
+3% +0%
Infection +2% +1%
Vomiting 4% NR
Stomatitis +3%–5% +0.5%
Nail disorders +2% NR
Edema +0.5% NR
Neurosensory–
neuromotor
+0 +1% (+15% grade 2)
Arthralgia/myalgia +0.5% NR
Cardiac +0.5% 0.2%
Toxic deaths +0.3%–0.6% +0%
Table 4. Taxanes efficacy related to hormonal receptor status (data are
reported as hazard ratio and 95% CI)
Study HR HR+
BCIRG 001 0.69 (0.49–0.97) 0.72 (0.56–0.92)
GEICAM 9906 Significant Significant
CALGB 9344 0.72 (0.59–0.86)a 0.91 (0.78–1.07)
E 2197 1.21 (0.92–1.59)b 0.99 (0.75–1.30)b
NSABP B-28 0.77 (0.65–0.92) 0.90 (0.72–1.12)
HR, hormonal receptor negative, estrogen and progesterone.
HR+, hormonal receptor positive, estrogen and/or progesterone.
aHormonal receptor negative or unknown.
bData referred to ER instead of HR and to ER+ instead of HR+.
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Another exploratory analysis showed that paclitaxel given every
3 weeks is inferior to docetaxel every 3 weeks in terms of disease-
free survival, even if the difference was not statistically
significant (HR 1.13, CI 95% 0.94–0.36; P = 0.20).
Based on the results in both metastatic and early breast
cancer, it seems that the best way to administer taxanes is either
weekly paclitaxel or docetaxel every 3 weeks.
can taxanes substitute anthracyclines
in the adjuvant setting?
A recent trial compared four cycles of AC regimen with four
cycles of TC (docetaxel 75 mg/m2 and cyclophosphamide 600
mg/m2) [16]. After a median follow-up of 66 months, TC was
associated with a statistical improvement in disease-free survival
(HR = 0.67, P = 0.01), with a favorable trend in overall survival
(HR = 0.76, P = 0.13). TC regimen was associated with more
incidence of febrile neutropenia (6% versus 3%, P = 0.03),
edema, myalgia and arthralgia of every grade but with less
nausea and vomiting grade 3–4 (2% versus 7% and <1% versus
5%, respectively).
The role of taxanes instead of anthracyclines is also under
evaluation in HER2-positive disease. The BCIRG 006 [17] trial
compared the efficacy of two different chemotherapy regimens
associated to trastuzumab. The first one was a classical AC
followed by docetaxel plus trastuzumab (AC–TH), the second
regimen was docetaxel and carboplatin given concurrently with
trastuzumab (TCH). This trial was designed in order to reduce/
avoid the cardiotoxicity induced by the combination of
anthracyclines and trastuzumab. After a median follow-up of 23
months, there was no statistically significant difference between
the two trastuzumab-containing arms. However, a favorable
trend in disease-free survival for the anthracycline-based arm
was observed (98 versus 77 events, P = 0.16). There was more
cardiotoxicity in the AC–TH arm compared with the TCH arm.
Clinically significant cardiac events were 2.34% (CI 95%
1.52–3.44) and 1.33% (CI 95% 0.73–2.21) in the AC–TH and
TCH arms, respectively. Asymptomatic decline of LVEF (>10%)
was significantly higher in the AC–TH arm compared with the
TCH arm (17.3% versus 8.0%, respectively). One interesting
finding of this trial was that 35% HER2-positive breast cancer
are associated with amplification of topoisomerase II-a, the
therapeutic target of anthracyclines. In amplified diseases,
the use of anthracyclines was more effective than its non-use,
while results between the two arms were comparable if
topoisomerase II-a was not amplified.
The suggestion of these trials is that TCH in HER2-positive
patients and TC in HER2-negative patients represent
a treatment option, instead of anthracyclines, in a selected group
of patients.
taxanes efficacy and hormonal receptor
status
The EBCTCG (Early Breast Cancer Trialists’ Collaborative
Group) [18] evaluated the impact of polichemotherapy versus
no adjuvant treatment in young (<50 years) and older (50–69
years) women in terms of recurrence and mortality. The
absolute benefit at 15 years appears to be about three times as
great for younger than for older women. In fact, between
patients <50 years the absolute reduction of recurrence at
15 years was 12.3%, while in older women it was 4.1%.
Absolute reduction of death was 10.0% in younger patients,
3.0% in older patients.
In younger women, polichemotherapy versus no adjuvant
therapy is equally effective in ER-poor as well as in ER-positive
disease, with a reduction of death risk of more than 30%. In
older women, polichemotherapy is more effective in ER-poor
than in ER-positive disease, 26% versus 5%, respectively.
However, differences exist based on the type of chemotherapy
used. If we consider the benefit of anthracyclines compared to
CMF, the proportional effect on breast cancer mortality is
independent from ER status. Among younger women,
anthracyclines reduce breast cancer mortality of 39% and 36%
in ER-poor and ER-positive disease, respectively (difference
2p = 0.7), whereas among older women the benefit is 24%
and 19% in ER-poor and ER-positive, respectively (difference
2p = 0.5).
On the other hand, results of subgroups analysis regarding
taxanes efficacy by hormonal receptor status are at least
heterogeneous. BCIRG 001 and GEICAM 9906 demonstrated
better efficacy of taxanes regardless of hormonal receptor status.
CALGB 9344 indicated that taxanes efficacy was evident only in
negative or unknown hormonal receptors patients.
Paradoxically, NSABP B-28 reported a statistically significant
benefit in terms of disease-free survival (HR = 0.77; CI 95%
0.65–0.92; P = 0.004) only in positive hormonal receptors.
Of note the chemotherapy regimen used in the CALGB and
NSABP trials was quite similar. Overall, hormonal receptor
status seems not to be a predictive factor on which the choice
of chemotherapy regimen should be based.
In conclusion, enough data are available to set taxanes as
a standard treatment for node-positive early breast cancer
patients. Studies are required in node-negative disease. Weekly
paclitaxel and every 3 weeks docetaxel seem to be the better
choice among the various taxane schedules. Hormonal receptor
status cannot be a guide to choice among the various
chemotherapy regimen.
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